Aardvark Therapeutics closed at $1.26 on Nov 4, up 2.44%, 92.0% below its 52-week closing high. Volume of 216.6K shares was 0.13× its 20-day average (below normal).
Split-adjusted performance: -75.0% over one month, -78.6% over six months, -87.9% over one year.
Short interest was 553.3K shares at the Oct 15 settlement, up 16.7% from the prior report (4.6% of float, 3.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AARDAardvark Therapeutics | $1.26 | +2.44% | −78.6% | — | — | — | $27.6M | |
| FLNAFilana Therapeutics | $0.5720 | −3.75% | — | — | — | — | $27.6M | Compare |
| BCTXBriacell Therapeutics | $3.19 | +5.98% | −23.1% | — | — | — | $27.9M | Compare |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
| RNAZTransCode Therapeutics | $1.60 | +1.91% | −78.7% | — | — | — | $27.1M | Compare |
| NXTCNextCure | $5.85 | −1.02% | −45.4% | — | — | — | $26.8M | Compare |
| ABVCABVC BioPharma | $1.00 | +1.51% | −9.1% | — | — | — | $26.7M | Compare |
| CELUCelularity | $0.8088 | −1.02% | −13.0% | −5.3% | 10.1% | — | $26.2M | Compare |
| ACETAdicet Bio | $3.10 | −2.21% | −63.7% | — | — | — | $29.0M | Compare |
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
